Press Releases

 
Press Releases
  Date Title View
Apr 23, 2013
- ACH-3102 deemed safe and well-tolerated following 12 weeks of therapy - - High barrier to resistance demonstrated with no on-treatment virologic breakthrough observed - - Novel NS5A inhibitor study supports differentiated profile of ACH-3102 - NEW HAVEN, Conn., April 23, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) ...
PDF
Apr 16, 2013
NEW HAVEN, Conn., April 16, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it has initiated an international Phase 2 clinical trial with sovaprevir and ACH-3102 for the treatment of genotype 1 chronic hepatitis C (HCV). The trial will evaluate an all-oral 12-week interferon-free regimen consisting of sov...
PDF
Mar 1, 2013
NEW HAVEN, Conn., March 1, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that members of the senior management team will be presenting a company overview at two upcoming investor conferences: Cowen and Company 33rd Annual Health Care Conference on Monday, March 4, 2013 at 2:50 p.m. ET at The Boston Marr...
PDF
Feb 27, 2013
NEW HAVEN, Conn., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that the underwriters exercised their option to purchase an additional 1,894,410 shares from Achillion in its previously announced underwritten public offering of common stock at a price to the public of $8.40 per share. The offering of...
PDF
Feb 21, 2013
NEW HAVEN, Conn., Feb. 21, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $8.40 per share. The net proceeds to Achillion from the sale of the shares, after deducting underwriting discounts and c...
PDF
Feb 20, 2013
- Conference call and webcast to be held today, February 20th, at 5:00 pm EST - NEW HAVEN, Conn., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve months ended December 31, 2012. For the three months ended December 31, 2012, the Company reported a net l...
PDF
Feb 20, 2013
NEW HAVEN, Conn., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that it has commenced an underwritten public offering of $125 million of its common stock. In connection with this offering, Achillion plans to grant the underwriters a 30-day option to purchase additional shares of its common stock. Ci...
PDF
Feb 19, 2013
NEW HAVEN, Conn., Feb. 19, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it plans to release fourth quarter and year-end 2012 financial results on Wednesday, February 20, 2013, after the market closes. Achillion will also host a conference call and live webcast to discuss these financial results and to ...
PDF
Feb 8, 2013
NEW HAVEN, Conn., Feb. 8, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Michael Kishbauch, President and Chief Executive Officer of Achillion, will present a corporate update at the Leerink Swann Global Healthcare Conference on Wednesday, February 13, 2013 at 3:30 p.m. EST at the Waldorf-Astoria Hotel i...
PDF
Jan 17, 2013
NEW HAVEN, Conn., Jan. 17, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, Senior Vice President of Business Development and Chief Commercial Officer of Achillion, will present a corporate update at the upcoming Noble Financial Capital Markets' Ninth Annual Equity Conference on Wednesday, J...
PDF
FirstPrevious
...
7
...
NextLast
Achillion Pharmaceuticals